Valuation: Climb Bio, Inc.

Market Cap 540M 492M 453M 412M 773M 49.99B 813M 5.51B 2.19B 27.3B 2.03B 1.98B 85.68B P/E 2026 *
-12.1x
P/E 2027 * -9.47x
Enterprise Value 339M 309M 284M 259M 485M 31.39B 510M 3.46B 1.38B 17.14B 1.27B 1.24B 53.8B EV / Sales 2026 *
-
EV / Sales 2027 * 276x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Climb Bio, Inc.

1 day-0.97%
1 week-11.29%
Current month-10.34%
1 month-14.91%
3 months-46.00%
6 months-12.64%
Current year+129.75%
1 week 8.9
Extreme 8.9
10.56
1 month 8.48
Extreme 8.485
12.44
Current year 3.46
Extreme 3.46
18.33
1 year 1.64
Extreme 1.635
18.33
3 years 1.05
Extreme 1.05
18.33
5 years 1.05
Extreme 1.05
18.76
10 years 1.05
Extreme 1.05
29.69
Manager TitleAgeSince
Chief Executive Officer 50 2024-06-26
Director of Finance/CFO 44 2025-09-30
Chief Tech/Sci/R&D Officer - 2025-10-20
Director TitleAgeSince
Director/Board Member 63 2021-01-31
Director/Board Member 50 2024-06-26
Director/Board Member 37 2024-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
9/28/26
RA Capital Management LP
ExerciceCompany 140,000 0.2437%
9/15/26 Sell

Director

-100,000 0.1741%
6/5/26 Free

Chairman

40,000 0.0699%
Change 5-day change 1-year change 3-year change Capi.($)
-0.97%-11.29%+431.21%+261.81% 540M
-2.49%-3.76%+50.31%+62.10% 63.66B
-0.63%-2.91%+6.20%+89.22% 58.56B
-2.37%-2.22%+22.87%+82.31% 54.19B
-2.19%-6.15%+11.92%+108.08% 44.66B
-1.89%-7.28%+13.22%+19.74% 40.51B
-0.93%-0.47%+19.73%+43.75% 36.27B
+1.11%-6.44%+130.68%+641.83% 34.89B
-0.80%+0.61%+77.26%+56.26% 32.26B
-2.17%+16.65%-29.21%+474.05% 31.01B
Average -1.33%-2.22%+73.42%+183.91% 40B
Weighted average by Cap. -1.48%-1.87%+32.70%+151.05%

Financials

2026 *2027 *
Net sales - 500K 455K 420K 382K 716K 46.3M 753K 5.11M 2.03M 25.29M 1.88M 1.84M 79.37M
Net income -57.89M -52.73M -48.58M -44.19M -82.91M -5.36B -87.14M -591M -235M -2.93B -217M -213M -9.19B -83.17M -75.75M -69.8M -63.49M -119M -7.7B -125M -849M -338M -4.21B -312M -305M -13.2B
Net Debt -201M -183M -169M -153M -288M -18.6B -302M -2.05B -815M -10.16B -754M -738M -31.88B -402M -366M -337M -307M -575M -37.2B -605M -4.1B -1.63B -20.32B -1.51B -1.48B -63.77B
Projected Income Statement - Annual - Climb Bio, Inc.
Logo Climb Bio, Inc.
Climb Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapeutics that address significant unmet need for patients living with immune-mediated diseases. Its lead product candidate, budoprutug, is a clinical-stage anti-CD19 monoclonal antibody (mAb) designed to deplete CD19-positive B cells. By targeting CD19, budoprutug has the potential to provide reductions in B cells and pathogenic autoantibodies. The Company is developing budoprutug for the treatment of primary membranous nephropathy (pMN), immune thrombocytopenia (ITP), and systemic lupus erythematosus (SLE). The Company is in Phase II clinical trial of budoprutug for pMN, Phase Ib/IIa clinical trial for ITP, and Phase Ib clinical trial of budoprutug for SLE. The Company is also developing CLYM116, an anti-APRIL (A Proliferation-Inducing Ligand) monoclonal antibody being developed for the treatment of immunoglobulin A nephropathy.
Employees
29
Date Price Change Volume
26-11-20 US$9.190 -0.97% 770,180
26-11-19 US$9.280 -0.22% 586,608
26-11-18 US$9.300 -4.91% 865,347
26-11-17 US$9.780 -1.61% 593,760
26-11-16 US$9.940 -4.05% 676,072
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Climb Bio, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
9.190USD
Average target price
28.40USD
Spread / Average Target
+209.03%
  1. Stock Market
  2. Stocks
  3. CLYM Stock